From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
ITF 3756 is a potent and selective HDAC6 inhibitor. ITF 3756 reduces in vitro the expression of PD-L1 on human monocytes and on CD8Tcells, and shows anti-tumor activity .
ODN 1585 is a potent inducer of IFN and TNFα production. ODN 1585 is a potent stimulator of NK (natural killer) function. ODN 1585 increases CD8+ T-cell function, including the CD8+ Tcell-mediated production of IFN-γ. ODN 1585 induces regression of established melanomas in mice. ODN 1585 can confer complete protection against malaria in mice. ODN 1585 sodium can be used for acute myelogenous leukemia (AML) and malaria research. ODN 1585 can be used as a vaccine adjuvant .
ERG245 is a BCAT1 inhibitor that enhances oxidative phosphorylation (OXPHOS) in CD8+Tcells by specifically inhibiting BCAT1 activity, thereby increasing the cytotoxicity of CD8+Tcells. ERG245, in combination with Pembrolizumab (anti-PD-1, HY-P9902A), promotes tumor regression. ERG245 can be used in research related to immuno-oncology .
ODN 1585 is a potent inducer of IFN and TNFα production. ODN 1585 is a potent stimulator of NK (natural killer) function. ODN 1585 increases CD8+ T-cell function, including the CD8+ Tcell-mediated production of IFN-γ. ODN 1585 induces regression of established melanomas in mice. ODN 1585 can confer complete protection against malaria in mice. ODN 1585 can be used for acute myelogenous leukemia (AML) and malaria research. ODN 1585 can be used as a vaccine adjuvant .
ORIC-533 is an orally active, selective CD73 inhibitor with AMP-competition. ORIC-533 restores immunosuppressed CD8+ Tcell proliferation and activation, triggers significant lysis and cell death of multiple myeloma cells in the bone marrow microenvironment .
PD-1/PD-L1-IN-54 (Compound 6) is a moderately affinic PD-1/PD-L1 inhibitor (KD: PD-1, 55.8 μM; PD-L1, 46.4 μM; IC50: 88.6 μM). PD-1/PD-L1-IN-54 inhibits PD-1/PD-L1 interactions and shows anticancer activity by activating CD8+Tcells, upregulating PD-1 expression, and increasing secretion of IFN-γ and IL-2. PD-1/PD-L1-IN-54 inhibits cancer cell proliferation and promotes apoptosis. PD-1/PD-L1-IN-54 also regulates Tcell immunity through the PI3K/Akt pathway correlated with PD-1/PD-L1 .
CFP10 (71–85) is a biological active peptide. (CFP1071–85, that elicited IFN-γ production and CTL activity by both CD4+ and CD8+ Tcells from persons expressing multiple MHC class II and class I molecules)
Eftilagimod alfa (IMP321) is a recombinant LAG-3Ig fusion protein that binds to MHC class II. Eftilagimod alfa mediates antigen-presenting cell (APC) activation followed by CD8T-cell activation. Eftilagimod alfa can be used for metastatic melanoma and metastatic breast carcinoma research .
Lipid C2 is an ionizable cationic lipid that has been used in the formation of lipid nanoparticles (LNP) for mRNA delivery in vivo. LNPs containing Lipid C2 and encapsulating an mRNA reporter selectively accumulate in the liver and spleen but not the heart, lungs, or kidneys in mice. LNP containing Lipid C2 and encapsulating mRNA encoding the Epstein-Barr virus (EBV) protein latent membrane protein 2 (LMP-2), in combination with an anti-programmed cell death protein 1 (PD-1) antibody, decrease tumor volume and reverse Tcell exhaustion, as well as increase the percentage of CD3 +CD8 + central and CD3 +CD8 + effector memory Tcells and decrease the percentage of CD3 +Tcells expressing Pd-1, in the spleen in a CT26 murine EBV-infected colon cancer model .
Belapectin (GR-MD-02) is a Galectin-3 (Gal-3) inhibitor. Belapectin drives tumor-induced immunosuppression by inducing TcellApoptosis. Belapectin promotes tumor regression and improves survival of tumor-bearing mice through a CD8+ Tcell-dependent mechanism. Belapectin binds to Gal-3 with affinity Ki of 2.8 μM .
PD-1/PD-L1-IN-50 (Compound LG-12) is a PD-1/PD-L1 inhibitor. PD-1/PD-L1-IN-50 increases the secretion of IFN-γ to promote CD8 + Tcell activation, and activates the antitumor immunity of Tcells .
CSF1R-IN-22 (Compound C19) is an orally effective CSF-1R selective inhibitor (IC50<6 nM). CSF1R-IN-22 enhances the secretion of CXCL9 from M2 macrophages, increases CD8+Tcell infiltration. CSF1R-IN-22 boosts anti-tumor immune responses of anti-PD-1, and induces apoptosis in tumor cells. CSF1R-IN-22 can effectively reprogram M2-like TAMs (tumor-associated macrophages) to the M1 phenotype and reshape the TME by inducing the recruitment of CD8+Tcells into tumors and reducing the infiltration of immunosuppressive Tregs and MDSCs .
WS-917 is a potent and orally active ABCB1 modulator. WS-917 enhances ABCB1 ATPase activity. WS-917 significantly enhances the antitumor effect of paclitaxel combined with anti-PD-1 antibody. WS-917 promotes CD8+T-cell activation .
N6F11 is a selective ferroptosis inducer, and can selectively induce ferroptosis by targeting TRIM25-mediated GPX4 degradation in cancer cells while sparing immune cells. N6F11 initiates HMGB1-dependent antitumor immunity mediated by CD8+Tcells .
KHK-6 is an inhibitor for serine/threonine kinase hematopoietic progenitor kinase 1 (HPK 1) with an IC50 of 20 nM. KHK-6 enhances CD3/CD28-induced cytokine production, enhances CD69, CD25 and HLA-DR markers on CD4+ and CD8+ Tcells, and enhances Tcell-mediated killing activity of SKOV3 and A549 cells .
PD-1/PD-L1-IN-27 is a potent PD-1/PD-L1 inhibitor with an IC50 value of 134 nM. PD-1/PD-L1-IN-27 shows antitumor effects with low Tcell cytotoxicity. PD-1/PD-L1-IN-27 has the ability to activate CD8+Tcells and reduces Tcell exhaustion .
Influenza A NP (383-391) (HLA-B27) is a peptide sequence derived from tetanus toxin. Influenza A NP (383-391) (HLA-B27) is a broadly immunogenic CD4+ T helper cell epitope that enhances CD8+ cytotoxic T lymphocyte (CTL) responses. Influenza A NP (383-391) (HLA-B27) can be used in breast cancer research .
Influenza NP (311-325) is a biologically active peptide derived from the influenza virus nucleoprotein (NP). The NP protein is an MHC class II restricted epitope that elicits host immune responses during viral infection. Influenza NP (311-325) elicits the most potent interferon gamma (IFN-γ) production without stimulating CD8Tcells in mice.
Zelasudil (RXC007) is an orally active, highly selective small molecule Rho-associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor with anti-fibrotic efficacy. Zelasudil elicits positive immunomodulatory effects in metastatic pancreatic tumors with increase of CD8+ and CD4+ Tcell infiltrate into the tumor cortex and reduction in immunosuppressive FOXP3+ regulatory Tcells at the tumor border. Zelasudil is promising for research of pancreatic ductal adenocarcinoma .
PD-1/PD-L1 inhibitory peptide C8 is inhibits PD-1/PD-L1 interaction, promotes the activation of CD8+ and CD4+ Tcells, and increases the IFN-γ secretion. PD-1/PD-L1 inhibitory peptide C8 exhibits antitumor efficacy in mouse model .
PD-1/ PD-L1-in-38 is a PD-1/PD-L1 inhibitor, which can inhibit the proliferation of tumor cells, promote the secretion of INF-γ by CD8+Tcells, and inhibit the ability of PD-1/PD-L1 signal transduction. PD-1/PD-L1-IN-38 has antitumor activity .
JNU-0921 is a potent and orally active CD137 inhibitor. JNU-0921 increases the mRNA expression of IFN-γ and GZMB. JNU-0921 induces luciferase activity with an EC50 value of 64.07 nM.JNU-0921 enhances effector and memory function of cytotoxic CD8+Tcells (CTLs) and alleviates their exhaustion. JNU-0921 also skews polarization of helper Tcells toward T helper 1 type and enhances their activity to boost CTL function. JNU-0921 shows anticancer activity .
Gusperimus is a fully synthetic racemate that has a novel mechanism of action by binding to the intracellular heat shock protein hsp70 and interfering with intracellular signal transduction. This mechanism of action can enhance the effect of immunosuppressive therapy. Gusperimus can inhibit the differentiation of Tcells into cytotoxic Tcells, reduce the expression of IL-2 receptors on CD4 and CD8cells, and inhibit IFN-γ-induced B cell maturation. In addition, when used with cyclosporine, tacrolimus or mycophenolate mofetil, Gusperimus can enhance the immunosuppressive effect and prevent allogeneic transplant rejection.
Soquelitinib (CPI-818) is an orally active and highly selective covalent interleukin-2-inducible kinase (ITK) inhibitor. Soquelitinib is active in six different models of Tcell-mediated inflammatory and immune disease, including acute and chronic asthma, pulmonary fibrosis, systemic sclerosis (scleroderma), psoriasis, and acute graft versus host disease with Th2 cytokine product inhibition. Soquelitinib increases tumor infiltration of normal CD8+cells that possess enhanced T effector function .
PD-1/PD-L1-IN-13 (Compound 43) is a potent immune checkpoint PD-1/PD-L1 inhibitor with an IC50 value of 10.2 nM. PD-1/PD-L1-IN-13 promots CD8+Tcell activation and delays the tumor growth in the Hepa1-6 syngeneic mouse model .
Nogapendekin alfa, a soluble protein subunit of a human interleukin (IL)-15 variant, is a superagonist of IL-15. Nogapendekin alfa promotes the proliferation and viability of immune cells. Nogapendekin alfa combines with Inbakicept (HY-P99661) at a ratio of 2:1, to form N-803 (Nogapendekin alfa inbakicept), an IL-15 cytokine antibody fusion protein. N-803 reduces tumor burden by activation of NK cells and CD8+Tcells .
SMU-L11 is a specific TLR7 agonist (EC50=0.024 μM), which recruits MyD88 adapter protein and activates downstream NF-κB and MAPK signaling pathways. In murine models, SMU-L11 significantly enhances immune cell activation and promotes the proliferation of CD4 +T and CD8+Tcells, thereby directly killing tumor cells and inhibiting tumor growth. SMU-L11 can be used for cancer research, and also has the potential for studying immune system diseases .
PD-1-IN-25 (compound 43) is a potent PD-1/PD-L1 interaction inhibitor with an IC50 value of 10.2 nM in the HTRF assay. PD-1-IN-25 can promote CD8+ Tcell activation through inhibiting PD-1/PD-L1 cellular signaling. PD-1-IN-25 delays the tumor growth .
EBV BZLF1 (190-197) is an immunodominant CEF-controlling peptide derived from Epstein-Barr virus (EBV). EBV BZLF1 (190-197) is a suitable epitope for CD8+ Tcells to stimulate the release of IFNg. CTL responses to EBV BZLF1 (190-197) are diverse and cross-recognize similar peptides from both host self-proteins and bacterial proteins. EBV BZLF1 (190-197) can be used to study autoimmune diseases .
NY-ESO-1 (157-165) peptide is a peptide fragment from NY-ESO-1 protein. NY-ESO-1 (157-165) peptide can activate the immune system, especially for HLA-A2 positive individuals, it can be recognized by CD8+ Tcells, thus triggering an immune response. NY-ESO-1 (157-165) peptide is expressed in a variety of tumors and can be used as a target for tumor immunotherapy .
KY-1044 (Alomfilimab; SAR 445256) is a fully human IgG1 antibody targeting inducible costimulatory receptor (ICOS). KY-1044 depletes ICOS highcells via antibody-dependent cellular cytotoxicity (ADCC) through the engagement of FcgRIIIa. KY-1044 act as a costimulatory molecule on cells expressing lower ICOS levels, such as CD8+ TEffcells (through FcgR-dependent clustering). KY-1044 exploit the differential expression of ICOS on T-cell subtypes to improve the intratumoral immune contexture and restore an antitumor immune response .
NY-ESO-1 (157-165) peptide (TFA) is a peptide fragment from NY-ESO-1 protein. NY-ESO-1 (157-165) peptide (TFA) can activate the immune system, especially for HLA-A2 positive individuals, it can be recognized by CD8+ Tcells, thus triggering an immune response. NY-ESO-1 (157-165) peptide (TFA) is expressed in a variety of tumors and can be used as a target for tumor immunotherapy .
(2R,3S)-PD-1/PD-L1-IN-38 (Compound (±)-13e) is an orally active Ah receptor (AhR) antagonist with in vivo and in vitro anticancer activity. (2R,3S)-PD-1/PD-L1-IN-38 promotes the secretion of INF-γ by CD8+T cells and inhibits the signal transduction of PD-1/PD-L1 .
LAG-3 cyclic peptide inhibitor C25 is a LAG-3 inhibitor. LAG-3 cyclic peptide inhibitor C25 has a high affinity with human LAG-3 protein with a Kd value of 0.66 μM. LAG-3 cyclic peptide inhibitor C25 can block the interaction of LAG-3 with HLA-DR (MHC-II) and activate CD8+Tcells. LAG-3 cyclic peptide inhibitor C25 can be used in the study of cancer .
Antitumor agent-36 possesses potent anti-proliferative and anti-metastasis activities. Antitumor agent-36 induces serious DNA damage and further leads to high expression of γ-H2AX and p53. Antitumor agent-36 promotes apoptosis of tumor cells through mitochondrial apoptotic pathway Bcl-2/Bax/caspase3. Antitumor agent-36 significantly improves immune response through restraining the expression of PD-L1 to increase CD3+ and CD8+ T infiltrating cells in tumor tissues .
Antitumor agent-37 possesses potent anti-proliferative and anti-metastasis activities. Antitumor agent-37 induces serious DNA damage and further leads to high expression of γ-H2AX and p53. Antitumor agent-37 promotes apoptosis of tumor cells through mitochondrial apoptotic pathway Bcl-2/Bax/caspase3. Antitumor agent-37 significantly improves immune response through restraining the expression of PD-L1 to increase CD3+ and CD8+ T infiltrating cells in tumor tissues .
Blontuvetmab (AT 004) is a caninized CD20 monoclonal antibody and is also a potent, selective, highly potent antagonist of A2aR receptor. Blontuvetmab behaves as Nociceptin (HY-P0183)/Orphanin (HY-P0183) FQ receptor (NOP) agonists displaying weak NOP affinity. Blontuvetmab inhibits 5'-N-Ethylcarboxamidoadenosine (NECA)-mediated A2aR activation and significantly reverses the ability of adenosine to suppress CD8Tcell activation, increasing levels of cytokines such as IFN-γ. Blontuvetmab Blontuvetmab can be used for the research of Canine B-cell lymphoma .
IHMT-PI3K-455 (Compound 15u) is a potent, selective, orally active PI3Kγ/δ dual inhibitor with IC50s of 7.1 nM and 0.57 nM for PI3Kγ and PI3Kδ, respectively. IHMT-PI3K-455 suppresses the AKT phosphorylation. IHMT-PI3K-455 inhibits tumor growth by recruiting and activating more CD8+ killing Tcells.IHMT-PI3K-455 is used in cancer research .
EP4 receptor antagonist 7 (Compound 14) is an antagonist of the prostaglandin E2 (PGE2) receptor subtype EP4 with an IC50 value of 1.1 nM. EP4 receptor antagonist 7 inhibits PGE2-induced β-arrestin recruitment in HEK293 cells with an IC50 value of 0.9 nM. EP4 receptor antagonist 7 decreases PGE2-induced expression of mRNA encoding IL-4, macrophage mannose receptor 1 (Mrc1), chitinase-like protein 3 (Chil3), chemokine (C-X-C) motif ligand 1 (Cxcl1), triggering receptor expressed on myeloid cells 2 (Trem2), and arginase-1 (Arg1), in RAW 264.7 macrophages. EP4 receptor antagonist 7 combined with an anti-PD-1 antibody inhibits tumor growth and increases infiltration of CD 8+Tcells into tumors in a CT26 murine colon cancer model .
Monalizumab (IPH2201) is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC) .
SIIVFEKL TFA is a variant of the major MHC class I-restricted epitope SIINFEKL. SIIVFEKL TFA is an antigenic peptide, that can stimulate specific Tcells in experimental settings to study the competitive interaction between Tcells. SIIVFEKL TFA exhibits low affinity for the OT-I Tcell receptor (TCR), and can be used for detection of CD8+ Tcells .
SIYNFEKL TFA is a variant of major MHC class I-restricted epitope SIINFEKL. SIYNFEKL TFA is an antigenic peptide, that can stimulate specific Tcells in experimental settings to study the competitive interaction between Tcell. SIYNFEKL TFA exhibits low affinity for the OT-I Tcell receptor (TCR), and can be used for detection of CD8+ Tcells .
The AAV-8 NSL epitope is a specific CD8+ Tcell epitope identified from the capsid of an adeno-associated virus (AAV) serotype 8. The AAV-8 NSL epitope has a high affinity for MHC I molecules and is able to bind to MHC I molecules, thereby activating CD8+ Tcells. The AAV-8 NSL epitope can be used to study the impact of Tcell-mediated immune responses on AAV-mediated gene transfer .
AAV2 Epitope is a biological active peptide. (This peptide is the capsid derived immunodominant adeno-associated virus 2 (AAV2), CD8Tcell epitope. Liver toxicity observed in a clinical trial of AAV2 delivered systemically to patients with hemophilia was ascribed to killing of vector-transduced hepatocytes by capsid-specific T-cells.)
CFP10 (71–85) is a biological active peptide. (CFP1071–85, that elicited IFN-γ production and CTL activity by both CD4+ and CD8+ Tcells from persons expressing multiple MHC class II and class I molecules)
Influenza A NP (383-391) (HLA-B27) is a peptide sequence derived from tetanus toxin. Influenza A NP (383-391) (HLA-B27) is a broadly immunogenic CD4+ T helper cell epitope that enhances CD8+ cytotoxic T lymphocyte (CTL) responses. Influenza A NP (383-391) (HLA-B27) can be used in breast cancer research .
Influenza NP (311-325) is a biologically active peptide derived from the influenza virus nucleoprotein (NP). The NP protein is an MHC class II restricted epitope that elicits host immune responses during viral infection. Influenza NP (311-325) elicits the most potent interferon gamma (IFN-γ) production without stimulating CD8Tcells in mice.
PD-1/PD-L1 inhibitory peptide C8 is inhibits PD-1/PD-L1 interaction, promotes the activation of CD8+ and CD4+ Tcells, and increases the IFN-γ secretion. PD-1/PD-L1 inhibitory peptide C8 exhibits antitumor efficacy in mouse model .
HLA-B*0801-binding EBV peptide is an Epstein-Barr virus (EBV) epitope FLRGRAYGL. HLA-B*0801-binding EBV peptide can bind to the HLA-B*0801 molecule. HLA-B*0801-binding EBV peptide can be presented to CD8+ Tcells through HLA-B*0801 to activate a specific immune response .
EBV BZLF1 (190-197) is an immunodominant CEF-controlling peptide derived from Epstein-Barr virus (EBV). EBV BZLF1 (190-197) is a suitable epitope for CD8+ Tcells to stimulate the release of IFNg. CTL responses to EBV BZLF1 (190-197) are diverse and cross-recognize similar peptides from both host self-proteins and bacterial proteins. EBV BZLF1 (190-197) can be used to study autoimmune diseases .
NY-ESO-1 (157-165) peptide is a peptide fragment from NY-ESO-1 protein. NY-ESO-1 (157-165) peptide can activate the immune system, especially for HLA-A2 positive individuals, it can be recognized by CD8+ Tcells, thus triggering an immune response. NY-ESO-1 (157-165) peptide is expressed in a variety of tumors and can be used as a target for tumor immunotherapy .
IE1 peptide refers to an antigenic peptide encoded by the immediate early (IE) gene of mouse cytomegalovirus (mCMV). IE1 peptide is one of the key antigenic peptides expressed during mCMV infection, plays a role in transcriptional activation in the life cycle of mCMV, and is one of the earliest genes expressed in the viral replication cycle. IE1 peptide is an important target for CD8+ Tcell response and can be used to study the host immune response to mCMV infection .
NY-ESO-1 (157-165) peptide (TFA) is a peptide fragment from NY-ESO-1 protein. NY-ESO-1 (157-165) peptide (TFA) can activate the immune system, especially for HLA-A2 positive individuals, it can be recognized by CD8+ Tcells, thus triggering an immune response. NY-ESO-1 (157-165) peptide (TFA) is expressed in a variety of tumors and can be used as a target for tumor immunotherapy .
H2-D b restricted epitopes VSV Nucleoprotein (52-59) is a 9-mer peptide derived from the nucleoprotein of Vesicular Stomatitis Virus (VSV). H2-D b restricted epitopes VSV Nucleoprotein (52-59) binds to MHC class I molecules and presents itself to CD8+ Tcells, thereby activating cytotoxic T lymphocytes (CTLs), which can recognize and kill cells expressing the corresponding antigen. H2-D b restricted epitopes VSV Nucleoprotein (52-59) can be used in the development of CTL vaccines against Ebola virus .
LAG-3 cyclic peptide inhibitor C25 is a LAG-3 inhibitor. LAG-3 cyclic peptide inhibitor C25 has a high affinity with human LAG-3 protein with a Kd value of 0.66 μM. LAG-3 cyclic peptide inhibitor C25 can block the interaction of LAG-3 with HLA-DR (MHC-II) and activate CD8+Tcells. LAG-3 cyclic peptide inhibitor C25 can be used in the study of cancer .
MCE Mouse CD8+TCells Negative Selection Kit is designed for the isolation of CD8+Tcells from single cell suspensions of mouse spleen cells and lymph nodes.
Ivuxolimab is an OX40 (also known as CD134; TNFRSF4) agonist monoclonal antibody. OX40 is a costimulatory receptor expressed on activated CD4 + and CD8+Tcells. Ivuxolimab shows antitumor activity, with potential immunostimulatory activity .
Eftilagimod alfa (IMP321) is a recombinant LAG-3Ig fusion protein that binds to MHC class II. Eftilagimod alfa mediates antigen-presenting cell (APC) activation followed by CD8T-cell activation. Eftilagimod alfa can be used for metastatic melanoma and metastatic breast carcinoma research .
KY-1044 (Alomfilimab; SAR 445256) is a fully human IgG1 antibody targeting inducible costimulatory receptor (ICOS). KY-1044 depletes ICOS highcells via antibody-dependent cellular cytotoxicity (ADCC) through the engagement of FcgRIIIa. KY-1044 act as a costimulatory molecule on cells expressing lower ICOS levels, such as CD8+ TEffcells (through FcgR-dependent clustering). KY-1044 exploit the differential expression of ICOS on T-cell subtypes to improve the intratumoral immune contexture and restore an antitumor immune response .
Blontuvetmab (AT 004) is a caninized CD20 monoclonal antibody and is also a potent, selective, highly potent antagonist of A2aR receptor. Blontuvetmab behaves as Nociceptin (HY-P0183)/Orphanin (HY-P0183) FQ receptor (NOP) agonists displaying weak NOP affinity. Blontuvetmab inhibits 5'-N-Ethylcarboxamidoadenosine (NECA)-mediated A2aR activation and significantly reverses the ability of adenosine to suppress CD8Tcell activation, increasing levels of cytokines such as IFN-γ. Blontuvetmab Blontuvetmab can be used for the research of Canine B-cell lymphoma .
Monalizumab (IPH2201) is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC) .
Nogapendekin alfa, a soluble protein subunit of a human interleukin (IL)-15 variant, is a superagonist of IL-15. Nogapendekin alfa promotes the proliferation and viability of immune cells. Nogapendekin alfa combines with Inbakicept (HY-P99661) at a ratio of 2:1, to form N-803 (Nogapendekin alfa inbakicept), an IL-15 cytokine antibody fusion protein. N-803 reduces tumor burden by activation of NK cells and CD8+Tcells .
PD-1/ PD-L1-in-38 is a PD-1/PD-L1 inhibitor, which can inhibit the proliferation of tumor cells, promote the secretion of INF-γ by CD8+Tcells, and inhibit the ability of PD-1/PD-L1 signal transduction. PD-1/PD-L1-IN-38 has antitumor activity .
(2R,3S)-PD-1/PD-L1-IN-38 (Compound (±)-13e) is an orally active Ah receptor (AhR) antagonist with in vivo and in vitro anticancer activity. (2R,3S)-PD-1/PD-L1-IN-38 promotes the secretion of INF-γ by CD8+T cells and inhibits the signal transduction of PD-1/PD-L1 .
CD8 alpha is an important immune glycoprotein that serves as a coreceptor for MHC class I:peptide complexes, linking T cells to antigens presented by APCs.It interacts with TCR and MHC class I, recruits LCK kinase, and initiates multiple signaling pathways.CD8 alpha Protein, Rat (HEK293, Fc) is the recombinant rat-derived CD8 alpha protein, expressed by HEK293 , with C-hFc labeled tag.
CD8A is an important immune glycoprotein that acts as a coreceptor for class I MHC:peptide complexes, linking T cells to antigens presented by APCs. It interacts with TCR and MHC class I, recruits LCK kinase, and initiates multiple signaling pathways. CD8 alpha Protein, Mouse (HEK293, His) is the recombinant mouse-derived CD8 alpha protein, expressed by HEK293 , with C-His labeled tag.
CD8A is an important immune glycoprotein that acts as a coreceptor for class I MHC:peptide complexes, linking T cells to antigens presented by APCs. It interacts with TCR and MHC class I, recruits LCK kinase, and initiates multiple signaling pathways. CD8 alpha Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived CD8 alpha protein, expressed by HEK293 , with C-hFc labeled tag.
CD8 alpha is an important immune glycoprotein that serves as a coreceptor for MHC class I:peptide complexes, linking T cells to antigens presented by APCs. It interacts with TCR and MHC class I, recruits LCK kinase, and initiates multiple signaling pathways. CD8 alpha Protein, Ferret (HEK293, His) is the recombinant CD8 alpha protein, expressed by HEK293 , with C-His labeled tag. The total length of CD8 alpha Protein, Ferret (HEK293, His) is 164 a.a., with molecular weight of 25-29 kDa.
CD8 alpha is an important immune glycoprotein that serves as a coreceptor for MHC class I:peptide complexes, linking T cells to antigens presented by APCs. It interacts with TCR and MHC class I, recruits LCK kinase, and initiates multiple signaling pathways. CD8 alpha Protein, Cynomolgus (HEK293, Fc) is the recombinant cynomolgus-derived CD8 alpha protein, expressed by HEK293 , with C-hFc labeled tag. The total length of CD8 alpha Protein, Cynomolgus (HEK293, Fc) is 182 a.a., with molecular weight of ~44.4 kDa.
CD8 beta is an important immune glycoprotein that serves as a coreceptor for MHC class I:peptide complexes, linking T cells to antigens presented by APCs. It interacts with TCR and MHC class I, recruits LCK kinase, and initiates multiple signaling pathways. CD8 beta Protein, Human (HEK293) is the recombinant human-derived CD8 beta protein, expressed by HEK293 , with tag free. The total length of CD8 beta Protein, Human (HEK293) is 170 a.a., with molecular weight of ~27.3 kDa.
CD8 beta is an important immune glycoprotein that serves as a coreceptor for MHC class I:peptide complexes, linking T cells to antigens presented by APCs. It interacts with TCR and MHC class I, recruits LCK kinase, and initiates multiple signaling pathways. CD8 beta Protein, Human (HEK293, His) is the recombinant human-derived CD8 beta protein, expressed by HEK293 , with C-6*His labeled tag. The total length of CD8 beta Protein, Human (HEK293, His) is 149 a.a., with molecular weight of 25-32 kDa.
CD8 alpha Protein is expressed on the surface of cytotoxic T cells. It plays a crucial role in immune responses by binding to major histocompatibility complex class I molecules on target cells, enhancing T cell activation and cytotoxicity. CD8 alpha Protein is also involved in immune regulation and tolerance. Understanding its functions can aid in developing immunotherapies and vaccines. CD8 alpha Protein, Human (Biotinylated, HEK293, His) is the recombinant human-derived CD8 alpha protein, expressed by HEK293 , with C-His labeled tag. The total length of CD8 alpha Protein, Human (Biotinylated, HEK293, His) is 161 a.a., with molecular weight of ~28 kDa.
CD8A is an important immune glycoprotein that acts as a coreceptor for class I MHC:peptide complexes, linking T cells to antigens presented by APCs. It interacts with TCR and MHC class I, recruits LCK kinase, and initiates multiple signaling pathways. CD8 alpha Protein, Mouse (Biotinylated, HEK293, His) is the recombinant mouse-derived CD8 alpha protein, expressed by HEK293 , with C-His labeled tag.
CD8 beta is an important immune glycoprotein that serves as a coreceptor for MHC class I:peptide complexes, linking T cells to antigens presented by APCs. It interacts with TCR and MHC class I, recruits LCK kinase, and initiates multiple signaling pathways. CD8 beta Protein, Human (HEK293, Fc) is the recombinant human-derived CD8 beta protein, expressed by HEK293 , with C-hFc labeled tag. The total length of CD8 beta Protein, Human (HEK293, Fc) is 170 a.a., with molecular weight of ~50 kDa.
CD8 beta is an important immune glycoprotein that serves as a coreceptor for MHC class I:peptide complexes, linking T cells to antigens presented by APCs. It interacts with TCR and MHC class I, recruits LCK kinase, and initiates multiple signaling pathways. CD8 beta Protein, Human (Biotinylated, HEK293) is the recombinant human-derived CD8 beta protein, expressed by HEK293 , with tag free. The total length of CD8 beta Protein, Human (Biotinylated, HEK293) is 170 a.a., with molecular weight of ~17.6 KDa.
CD8 alpha Protein is expressed on the surface of cytotoxic T cells. It plays a crucial role in immune responses by binding to major histocompatibility complex class I molecules on target cells, enhancing T cell activation and cytotoxicity. CD8 alpha Protein is also involved in immune regulation and tolerance. Understanding its functions can aid in developing immunotherapies and vaccines. CD8 alpha Protein, Human (HEK293, His-Avi) is the recombinant human-derived CD8 alpha protein, expressed by HEK293 , with C-His, C-Avi labeled tag. The total length of CD8 alpha Protein, Human (HEK293, His-Avi) is 161 a.a., with molecular weight of 31-35 kDa.
CD8 alpha Protein is expressed on the surface of cytotoxic T cells. It plays a crucial role in immune responses by binding to major histocompatibility complex class I molecules on target cells, enhancing T cell activation and cytotoxicity. CD8 alpha Protein is also involved in immune regulation and tolerance. Understanding its functions can aid in developing immunotherapies and vaccines. CD8 alpha Protein, Human (HEK293, His) is the recombinant human-derived CD8 alpha protein, expressed by HEK293 , with N-6*His labeled tag. The total length of CD8 alpha Protein, Human (HEK293, His) is 161 a.a., with molecular weight of ~28 kDa.
The CD8A, a vital immune glycoprotein, acts as a coreceptor for MHC class I:peptide complexes, connecting T-cells to antigens presented by APCs. Its interaction with TCR and MHC class I recruits LCK kinase, initiating diverse signaling pathways. This mechanism enables CTLs to recognize and eliminate infected and tumor cells. In NK-cells, CD8A homodimers provide a survival mechanism for conjugation and lysis of target cells, contributing to lymphocyte survival and differentiation into memory CD8 T-cells. The heterodimer forms disulfide-linked complexes and homodimers, interacting with HLA-A/B2M and LCK in a zinc-dependent manner. CD8A-CD8B Heterodimer Protein, Mouse (HEK293, Flag-His) is a recombinant protein dimer complex containing mouse-derived CD8A-CD8B Heterodimer protein, expressed by HEK293, with C-His, C-Flag labeled tag. CD8A-CD8B Heterodimer Protein, Mouse (HEK293, Flag-His), has molecular weight of ~45.9 (23.7+22.2) kDa.
CD8 alpha Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 26 kDa, targeting to CD8 alpha. It can be used for WB,IHC-P assays with tag free, in the background of Human, Hamster.
CD8 antigen, alpha polypeptide (p32); CD8a; CD8a antigen; CD8a molecule; CD8A_MOUSE; CD8A_HUMAN; Leu2; Leu2 T lymphocyte antigen; MAL; OKT8 T cell antigen; p32; T cell antigen Leu2; T cell co receptor; T-cell surface glycoprotein CD8 alpha chain; T-lymphocyte differentiation antigen T8/Leu-2; T8 T cell antigen.
WB, IHC-P, ICC/IF
Mouse
CD8 Antibody is an unconjugated, approximately 27 kDa, rabbit-derived, anti-CD8 polyclonal antibody. CD8 Antibody can be used for: WB, IHC-P, IHC-F, IF expriments in human, mouse, background without labeling.
ODN 1585 is a potent inducer of IFN and TNFα production. ODN 1585 is a potent stimulator of NK (natural killer) function. ODN 1585 increases CD8+ T-cell function, including the CD8+ Tcell-mediated production of IFN-γ. ODN 1585 induces regression of established melanomas in mice. ODN 1585 can confer complete protection against malaria in mice. ODN 1585 sodium can be used for acute myelogenous leukemia (AML) and malaria research. ODN 1585 can be used as a vaccine adjuvant .
ODN 1585 is a potent inducer of IFN and TNFα production. ODN 1585 is a potent stimulator of NK (natural killer) function. ODN 1585 increases CD8+ T-cell function, including the CD8+ Tcell-mediated production of IFN-γ. ODN 1585 induces regression of established melanomas in mice. ODN 1585 can confer complete protection against malaria in mice. ODN 1585 can be used for acute myelogenous leukemia (AML) and malaria research. ODN 1585 can be used as a vaccine adjuvant .
Inquiry Online
Your information is safe with us. * Required Fields.
